Approximately 35% of male cancer patients and 12% of female cancer patients at Paras Health were diagnosed with tobacco-related cancers
The company also announced results for the third quarter, reporting sales at Rs. 992 crore, flat versus year ago
Annual EBITDA margin expands by 170 basis points
This strategic move positions Sudeep Pharma to seamlessly integrate high-end premix capabilities with its mineral portfolio
MANEUVER met all five key secondary endpoints, with statistically significant and clinically meaningful improvements in pain, stiffness, range of motion, physical function, and decrease in tumor volume
The initiative was announced at World Hypertension Congress, Chennai
The company reported sustained increase in formulations' share despite slowdown in productivity of Gagillapur facility
For FY25, Revenue from operation grew 28.8 per cent YoY to Rs. 70.1 crore
During the quarter, US formulations revenue increased by 13.5 per cent YoY to Rs. 4,072 crore
Akums invested Rs. 272 crore in capital expenditure during FY25
Subscribe To Our Newsletter & Stay Updated
